Q1: Why do dialysis patients often feel extremely fatigued after treatment, and how can peptide nucleic acids help improve this condition?
A1: During dialysis (hemodialysis), while metabolic waste products are filtered from the blood, high–molecular-weight proteins—such as albumin and hemoglobin—may also be inadvertently removed. This loss of essential proteins can result in significant nutritional depletion, leaving patients feeling physically exhausted after treatment.
The advantage of peptide nucleic acids lies in their small-molecule protein structure. Due to their relatively small molecular size, they are less likely to be filtered out during dialysis and can remain in the body to provide sustained reparative support. Clinical cases indicate that a retired school principal undergoing dialysis experienced noticeably improved post-treatment stamina and faster recovery after supplementing with peptide nucleic acids.
Q2: For elderly individuals with low serum albumin levels who require frequent albumin injections, what tangible benefits can peptide nucleic acids provide?
A2: As people age, their efficiency in absorbing dietary protein may decline. When serum albumin levels fall below the normal threshold (e.g., under 2.5 g/dL), expensive albumin infusions are often administered to maintain vitality and physiological stability.
Peptide nucleic acids offer a more efficient oral supplementation alternative. Documented evidence shows that an elderly hospitalized patient increased their albumin level from below 2.5 g/dL to 2.8 g/dL within just three days of supplementation, successfully eliminating the need for continued albumin injections. This not only enhanced the patient’s autonomy in health management but also reduced the long-term financial burden on the family.